FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362543817> ?p ?o ?g. }

• W4362543817 endingPage "836" @default.
• W4362543817 startingPage "836" @default.
• W4362543817 abstract "Abstract mRNA is a new class of drugs that has the potential to revolutionize the treatment of brain tumors. Thanks to the COVID-19 mRNA vaccines and numerous therapy-based clinical trials, it is now clear that lipid nanoparticles (LNPs) are a clinically viable means to deliver RNA therapeutics. However, LNP-mediated mRNA delivery to brain tumors remains elusive. Over the past decade, numerous studies have shown that tumor cells communicate with each other via small extracellular vesicles, which are around 100 nm in diameter and consist of lipid bilayer membrane similar to synthetic lipid-based nanocarriers. We hypothesized that rationally designed LNPs based on extracellular vesicle mimicry would enable efficient delivery of RNA therapeutics to brain tumors without undue toxicity. We synthesized LNPs using four components similar to the formulation used in the mRNA COVID-19 vaccines (Moderna and Pfizer): ionizable lipid, cholesterol, helper lipid and polyethylene glycol (PEG)-lipid. For the in vitro screen, we tested ten classes of helper lipids based on their abundance in extracellular vesicle membranes, commercial availability, and large-scale production feasibility while keeping rest of the LNP components unchanged. The transfection kinetics of GFP mRNA encapsulated in LNPs and doped with 16 mol% of helper lipids was tested using GL261, U87 and SIM-A9 cell lines. Several LNP formations resulted in stable transfection (upto 5 days) of GFP mRNA in all the cell lines tested in vitro. The successful LNP candidates (enabling &gt;80% transfection efficacy) were then tested in vivo to deliver luciferase mRNA to brain tumors via intrathecal administration in a syngeneic glioblastoma (GBM) mouse model, which confirmed luciferase expression in brain tumors in the cortex. LNPs were then tested to deliver Cre recombinase mRNA in syngeneic GBM mouse model genetically modified to express tdTomato under LoxP marker cassette that enabled identification of LNP targeted cells. mRNA was successfully delivered to tumor cells (70-80% transfected) and a range of different cells in the tumor microenvironment, including tumor-associated macrophages (80-90% transfected), neurons (31-40% transfected), neural stem cells (39-62% transfected), oligodendrocytes (70-80% transfected) and astrocytes (44-76% transfected). Then, LNP formulations were assessed for delivering Cas9 mRNA and CD81 sgRNA (model protein) in murine syngeneic GBM model to enable gene editing in brain tumor cells. Sanger sequencing showed that CRISPR-Cas9 editing was successful in ~94% of brain tumor cells in vivo. In conclusion, we have developed a library of safe LNPs that can transfect GBM cells in vivo with high efficacy. This technology can potentially be used to develop novel mRNA therapies for GBM by delivering single or multiple mRNAs and holds great potential as a tool to study brain tumor biology. Citation Format: Saigopalakrishna S. Yerneni, Juliana H. Azambuja, Peter C. Lucas, Linda McAllister-Lucas, Kathryn A. Whitehead. Enabling mRNA medicine for brain tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 836." @default.
• W4362543817 created "2023-04-06" @default.
• W4362543817 creator A5010666650 @default.
• W4362543817 creator A5034299577 @default.
• W4362543817 creator A5040413965 @default.
• W4362543817 creator A5060040445 @default.
• W4362543817 creator A5075263409 @default.
• W4362543817 date "2023-04-04" @default.
• W4362543817 modified "2023-10-16" @default.
• W4362543817 title "Abstract 836: Enabling mRNA medicine for brain tumors" @default.
• W4362543817 doi "https://doi.org/10.1158/1538-7445.am2023-836" @default.
• W4362543817 hasPublicationYear "2023" @default.
• W4362543817 type Work @default.
• W4362543817 citedByCount "0" @default.
• W4362543817 crossrefType "journal-article" @default.
• W4362543817 hasAuthorship W4362543817A5010666650 @default.
• W4362543817 hasAuthorship W4362543817A5034299577 @default.
• W4362543817 hasAuthorship W4362543817A5040413965 @default.
• W4362543817 hasAuthorship W4362543817A5060040445 @default.
• W4362543817 hasAuthorship W4362543817A5075263409 @default.
• W4362543817 hasConcept C104317684 @default.
• W4362543817 hasConcept C105580179 @default.
• W4362543817 hasConcept C130316041 @default.
• W4362543817 hasConcept C150903083 @default.
• W4362543817 hasConcept C178790620 @default.
• W4362543817 hasConcept C18150654 @default.
• W4362543817 hasConcept C185592680 @default.
• W4362543817 hasConcept C202751555 @default.
• W4362543817 hasConcept C207001950 @default.
• W4362543817 hasConcept C2779820397 @default.
• W4362543817 hasConcept C41625074 @default.
• W4362543817 hasConcept C54009773 @default.
• W4362543817 hasConcept C55493867 @default.
• W4362543817 hasConcept C86803240 @default.
• W4362543817 hasConcept C95444343 @default.
• W4362543817 hasConceptScore W4362543817C104317684 @default.
• W4362543817 hasConceptScore W4362543817C105580179 @default.
• W4362543817 hasConceptScore W4362543817C130316041 @default.
• W4362543817 hasConceptScore W4362543817C150903083 @default.
• W4362543817 hasConceptScore W4362543817C178790620 @default.
• W4362543817 hasConceptScore W4362543817C18150654 @default.
• W4362543817 hasConceptScore W4362543817C185592680 @default.
• W4362543817 hasConceptScore W4362543817C202751555 @default.
• W4362543817 hasConceptScore W4362543817C207001950 @default.
• W4362543817 hasConceptScore W4362543817C2779820397 @default.
• W4362543817 hasConceptScore W4362543817C41625074 @default.
• W4362543817 hasConceptScore W4362543817C54009773 @default.
• W4362543817 hasConceptScore W4362543817C55493867 @default.
• W4362543817 hasConceptScore W4362543817C86803240 @default.
• W4362543817 hasConceptScore W4362543817C95444343 @default.
• W4362543817 hasIssue "7_Supplement" @default.
• W4362543817 hasLocation W43625438171 @default.
• W4362543817 hasOpenAccess W4362543817 @default.
• W4362543817 hasPrimaryLocation W43625438171 @default.
• W4362543817 hasRelatedWork W1566729005 @default.
• W4362543817 hasRelatedWork W2074915237 @default.
• W4362543817 hasRelatedWork W2138350991 @default.
• W4362543817 hasRelatedWork W2329851658 @default.
• W4362543817 hasRelatedWork W2409285845 @default.
• W4362543817 hasRelatedWork W2434195791 @default.
• W4362543817 hasRelatedWork W2904549422 @default.
• W4362543817 hasRelatedWork W3036327439 @default.
• W4362543817 hasRelatedWork W4232949972 @default.
• W4362543817 hasRelatedWork W4383032613 @default.
• W4362543817 hasVolume "83" @default.
• W4362543817 isParatext "false" @default.
• W4362543817 isRetracted "false" @default.
• W4362543817 workType "article" @default.